Helpful Guide,WARNING LETTER. December 12, 2025

The regulatory environment surrounding peptides and their associated claims is a dynamic and critical area for businesses operating within the health and wellness sector. As November 2025 unfolds, the U.S. Food and Drug Administration (FDA) continues its diligent oversight, issuing warning letters to entities that fail to comply with federal regulations. This article delves into the specifics of these FDA peptide warning letters 2025 November, providing essential insights for understanding the agency's enforcement actions and the implications for companies involved with peptides.

The FDA's commitment to safeguarding public health is underscored by its proactive approach to addressing misleading or unapproved claims for peptide products. In 2025, and particularly as observed in November 2025, the agency has been actively scrutinizing a range of companies, including telehealth providers and direct sellers of peptides. A significant trend highlighted by the serp data involves telehealth companies making unsubstantiated claims about GLP-1 products. For instance, numerous warning letters have been issued to approximately 30 telehealth companies for allegedly making false or misleading claims about compounded semaglutide and tirzepatide. These letters often cite violations such as implying sameness with FDA-approved products or obscuring product sourcing, as seen in actions against companies like Gram Peptides and Pinnacle Professional Research dba Pinnacle Peptides.

Understanding the types of warning letters on FDA's website is crucial for businesses to proactively ensure compliance. The FDA issues these letters to notify recipients of violations of federal law and to outline the steps required for correction. The FDA's warning letters serve as a formal notification, and while they do not constitute a legal action in themselves, they represent a critical juncture for a business to address compliance issues. The 2025 fiscal year saw a substantial number of warning letters issued, with reports indicating a total of 303 warning letters for drug and biologics products, an increase from the previous year. Specifically, the US FDA CDRH Warning Letters in 2025 totaled 695, with a significant portion related to drugs, tobacco, and food products.

The crackdown on unapproved peptides is not a new phenomenon, but it has intensified. During the COVID-19 pandemic, the FDA issued several warning letters to businesses promoting peptides with alleged "immune-boosting powers." More recently, the focus has expanded to include GLP-1 receptor agonists, with the FDA issuing warning letters to manufacturers and telehealth companies for illegal marketing and false claims. For example, New Life Pharma received a warning letter for refusing inspectors access to a GLP-1 manufacturing facility. Similarly, USApeptide.com was observed introducing unapproved and misbranded semaglutide and tirzepatide drug products into interstate commerce, leading to a warning letter in March 2025.

The FDA's enforcement actions in November 2025 and throughout 2025 signal a clear directive: companies must adhere to strict regulatory standards when marketing and selling peptide products. This includes ensuring that all claims are truthful, not misleading, and supported by scientific evidence. The FDA's efforts to prevent the illegal sale of compounded GLP-1s, particularly through telehealth platforms, are a significant aspect of their regulatory agenda. The FDA sends warning letters to 30 telehealth companies as part of a continued clampdown on misleading advertising for these popular weight-loss drugs.

For businesses seeking to understand how to avoid FDA warning letters or what to do if they receive one, seeking expert guidance is paramount. The FDA's actions in 2025 and the ongoing issuance of warning letters highlight the importance of meticulous record-keeping, transparent sourcing, and accurate product labeling. Companies should familiarize themselves with the types of FDA warning letters and the specific regulations governing peptide sales and marketing. The FDA's warning letters are a critical tool for maintaining a safe and regulated marketplace, and understanding their implications is essential for any entity involved in the peptide industry. The FDA's actions in November 2025 serve as a stark reminder of the need for robust compliance strategies.